ArticleTechniques in coloproctology2025
Clinicopathological features and prognosis of patients with colorectal Mucinous adenocarcinoma mixed with other pathological components: a nationwide retrospective study in China.
Article in Techniques in coloproctology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and pathological characteristics of mucinous adenocarcinoma in colon cancer: comparison with classic adenocarcinoma.BMC gastroenterology · 2026Article
- Anatomical Location Is Associated with Clinicopathological Features and Long-Term Oncological Outcomes in Mucinous Colorectal Adenocarcinoma: A Population-Based Analysis of 40,698 Patients from the SEER Database.Journal of clinical medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucinous adenocarcinoma (MAC) is typically admixed with other pathological components, including conventional adenocarcinoma, signet ring cell carcinoma, and/or neuroendocrine neoplasms. Specifically, signet ring cell differentiation (MASD) is defined as a signet ring cell component comprising less than 50% of the tumor, and neuroendocrine differentiation (MAND) is defined as a neuroendocrine component constituting less than 30%. Furthermore, MAC admixed with conventional adenocarcinoma was defined as classic mucinous adenocarcinoma (CMAC) in this study. Therefore, the study aimed to investigate the clinicopathologic and prognostic differences between patients with CMAC and those with either MASD or MAND [collectively termed mucous adenocarcinoma mixed with other pathological components (MAM)].
methodsWe collected data from a multi-institutional registry of patients who underwent surgical curative resection for histologically proven MAC between January 2016 and September 2021 at 22 medical institutions in China. Patients with MAC with percentage of signet ring cell ≥ 50% or percentage of neuroendocrine component ≥ 30% were excluded.
resultsA total of 2023 patients from 22 medical institutions who met the study criteria were included. MAM, compared to CMAC, showed more aggressive histologic features, including higher rates of lymphovascular invasion (47.0% vs. 18.0%, p < 0.01), perineural invasion (68.0% vs. 35.1%, p < 0.01), T4 stage (33.5% vs. 26.5%, p < 0.01), N2 stage (56.2% vs. 17.8%, p < 0.01), and TNM stage III disease (73.5% vs. 49.2%, p < 0.01). MAMs had lower 3-year overall survival compared to those with CMAC (66.7% vs. 81.6%, p < 0.01). Multivariable analysis indicated that MAMs, including MASD and MAND, was an independent prognostic factor for poor disease-free survival and overall survival.
conclusionOur analysis of a large patient cohort confirmed the aggressive clinicopathological features and poor prognostic outcomes of MAM, including MAND and MASD, compared with CMAC. These findings underscore the need for surveillance protocols for MAM in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.